Proteocyte AI

Transform how you manage oral precancer patients.

STRATICYTE® provides clinicians with an objective, AI-driven 5-year oral cancer risk assessment, helping to identify which dysplastic lesions may require closer surveillance or earlier intervention.

By supplementing traditional histopathology, STRATICYTE® supports more informed, confident, and personalized patient management.

Better risk insight leads to better decisions.

Learn how STRATICYTE® can support your practice:
👉 https://proteocyte.com/straticyte/


American Academy of Otolaryngology—Head and Neck Surgery American Academy of Oral Medicine American Academy of Oral and Maxillofacial Pathology - AAOMP American Association of Oral and Maxillofacial Surgeons - AAOMS American Cancer Society

Founded in 2011, Proteocyte AI is building a platform of solutions to predict cancer risk.

By leveraging key biomarkers, proprietary algorithms, advanced imaging, and digital pathology, we go beyond traditional diagnostics to deliver deeper insight into individual patient risk.

Our mission is simple:
Enable earlier detection. Support better decisions. Improve patient outcomes.

Learn about our innovative STRATICYTE® test and how it accurately predicts risk of oral cancer:
👉 https://proteocyte.com


Canadian Dental Association Canadian Partnership Against Cancer Société de recherche sur le cancer / Cancer Research Society Fondation québécoise du cancer Manitoba Dental Association NB Dental Society Newfoundland and Labrador Dental Association